購物車
幫助
021-54845833/15800441009
中文名稱：兔抗SHH多克隆抗體
英文名稱： Anti-SHH rabbit polyclonal antibody
別 名： TPT, HHG1, HLP3, HPE3, SMMCI, TPTPS, MCOPCB5
相關類別： 一抗
儲 存： 冷凍（-20℃）
宿 主： Rabbit
抗 原： SHH
反應種屬： Human, Mouse, Rat
標記物： Unconjugate
克隆類型： rabbit polyclonal
技術規格
|
Background: |
This gene encodes a protein that is instrumental in patterning the early embryo. It has been implicated as the key inductive signal in patterning of the ventral neural tube, the anterior-posterior limb axis, and the ventral somites. Of three human proteins showing sequence and functional similarity to the sonic hedgehog protein of Drosophila, this protein is the most similar. The protein is made as a precursor that is autocatalytically cleaved; the N-terminal portion is soluble and contains the signalling activity while the C-terminal portion is involved in precursor processing. More importantly, the C-terminal product covalently attaches a cholesterol moiety to the N-terminal product, restricting the N-terminal product to the cell surface and preventing it from freely diffusing throughout the developing embryo. Defects in this protein or in its signalling pathway are a cause of holoprosencephaly (HPE), a disorder in which the developing forebrain fails to correctly separate into right and left hemispheres. HPE is manifested by facial deformities. It is also thought that mutations in this gene or in its signalling pathway may be responsible for VACTERL syndrome, which is characterized by vertebral defects, anal atresia, tracheoesophageal fistula with esophageal atresia, radial and renal dysplasia, cardiac anomalies, and limb abnormalities. Additionally, mutations in a long range enhancer located approximately 1 megabase upstream of this gene disrupt limb patterning and can result in preaxial polydactyly. |
|
Applications: |
ELISA, IHC |
|
Name of antibody: |
SHH |
|
Immunogen: |
Synthetic peptide of human SHH |
|
Full name: |
Sonic hedgehog |
|
Synonyms： |
TPT, HHG1, HLP3, HPE3, SMMCI, TPTPS, MCOPCB5 |
|
SwissProt: |
Q15465 |
|
ELISA Recommended dilution: |
2000-10000 |
|
IHC positive control: |
Human breast cancer and Human colon cancer |
|
IHC Recommend dilution: |
50-200 |
